← Eichor
Study identifier: NCT06393764 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cancer-related Venous Thromboembolic Disease - Cohort Study

Condition: Thrombosis Embolism · Thromboses, Venous · Cancer  ·  Sponsor: University Hospital, Brest

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Françis Couturaud, Pr  ·  +33298347348  ·  francis.couturaud@chu-brest.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Brest University HospitalBrest, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06393764